CAeditome Logo

Home

Download

Statistics

Landscape

Help

Contact
Center for Computational Systems Medicine
Soverview

1. Gene summary of enriched editing regions

Soverview

2. Tumor-specific enriched editing regions

Comparison of enriched editing regions between tumor and normal.

Correlation of enriched editing regions with tumor stages.

Associations of enriched editing regions with cancer survival.

Soverview

3. Enriched editing regions and immune related genes

Soverview

4. Enriched editing regions and immune related splicing

Soverview

5. Enriched editing regions and immune infiltration

Soverview

6. Enriched editing regions and immune gene sets

Correlation of enriched editing regions with epithelial-mesenchymal transition.

Correlations of enriched editing regions with hypoxic.

Associations of enriched editing regions with hallmark gene sets from MSigDB.

Soverview

7. Enriched editing regions and drugs

Correlations between enriched editing regions and drug sensitivity.

Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: RAD51-AS1 (ImmuneEditome ID:100505648)

1. Gene summary of enriched editing regions for RAD51-AS1

check button Gene summary
Gene informationGene symbol

RAD51-AS1

Gene ID

100505648

GeneSynonymsTODRA
GeneCytomap

15q15.1

GeneTypencRNA
GeneDescriptionRAD51 antisense RNA 1 (head to head)|transcribed in the opposite direction of RAD51
GeneModificationdate20230329
UniprotID.
PubMed ID

check buttonUCSC image.
all structure

check buttonLocations of each EERs.
EERENSTENSGGeneNameRegionRepeatdsRNA structure
chr15:40688377-40688648:-ENST00000526635.1ENSG00000245849.5RAD51-AS1ncRNA_intronicAluSqchr15:40688377-40688648:-.alignment
chr15:40688377-40688648:-ENST00000533146.4ENSG00000245849.5RAD51-AS1ncRNA_intronicAluSqchr15:40688377-40688648:-.alignment
chr15:40690566-40694369:-ENST00000499988.2ENSG00000245849.5RAD51-AS1ncRNA_exonicMIRc,AluJr,L2,AluJr4,MamRep605,AluSx3,AluJo,AluSx,AluSg7,MER1B,MLT1O,AluSx1,(A)n,(AAAT)nchr15:40690566-40694369:-.alignment


Top

2. Tumor-specific enriched editing regions for RAD51-AS1


all structure

check buttonComparison of enriched editing regions between tumor and normal.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypePBoxplot
chr15:40690566-40694369:-BRCAEER1.4117e-03image
ENSG00000245849.5,RAD51-AS1BRCAEAG1.6723e-06image
chr15:40690566-40694369:-LUSCEER4.5481e-04image
ENSG00000245849.5,RAD51-AS1LUSCEAG2.3556e-03image
chr15:40690566-40694369:-THCAEER1.8445e-02image
ENSG00000245849.5,RAD51-AS1THCAEAG2.6595e-03image


Top

check buttonCorrelation of enriched editing regions with tumor stages.
* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.
* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeStageTypeAnovaPPRBoxplot


Top

check button Associations of enriched editing regions with cancer survival.
* Pkm<0.05 and Pcox<0.05.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypeIDPkmPcox_continuousHR_continuousKMPlot
chr15:40690566-40694369:-KIRPEER2.5284e-023.1966e-025.3423e+04image
ENSG00000245849.5,RAD51-AS1OVEAG2.8041e-023.6108e-027.9034e+00image

Top

3. Enriched editing regions and immune related genes for RAD51-AS1


all structure

check button Enriched editing regions and immune related genes.
* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeGenebetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr15:40690566-40694369:-ESCAEERENSG00000110880,CORO1C0.38021.8347e-031.7890e-090.4765imageNNCORO1CT_cells_regulatory_(Tregs)GSVA_HALLMARK_HYPOXIA
chr15:40690566-40694369:-ESCAEERENSG00000171314,PGAM10.32729.2731e-031.9962e-080.4481imageNNPGAM1T_cells_CD4_memory_restingGSVA_HALLMARK_P53_PATHWAY

More results



Top

4. Enriched editing regions and immune related splicing for RAD51-AS1


all structure

check button Enriched editing regions and immune related splicing.
* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeSplicingTypeSplicingGeneSplicingChrSplicingPositionbetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr15:40690566-40694369:-
ESCAEERESENSG00000150527.12chr1439319208:39319291:39320927:39321056:39326863:39327022-0.37368.5089e-036.9341e-10-0.4870imageNNNAT_cells_regulatory_(Tregs)GSVA_HALLMARK_HYPOXIA
ENSG00000245849.5,RAD51-AS1
ESCAEAGA3ENSG00000134644.11chr130981311:30981405:30980061:30980163:30980061:309801660.33753.1254e-021.6418e-070.4093imageNADAR;AUH;BCCIP;BUD13;CNBP;CPSF6;CSTF2T;DDX42;DDX54;DGCR8;DHX9;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FUS;FXR1;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP2;KHDRBS1;KHDRBS3;KHSRP;LARP7;LIN28;LIN28B;LSM11;MSI2;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM27;RBM47;RBM5;RNF219;SAFB2;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YWHAG;ZNF184NAB_cells_naiveGSVA_HALLMARK_HYPOXIA
ENSG00000245849.5,RAD51-AS1
ESCAEAGESENSG00000138443.11chr2203402705:203402734:203411284:203411371:203416907:203416972-0.37208.1265e-035.5967e-08-0.4232imageNADAR;AUH;BCCIP;BUD13;CNBP;CPSF6;CSTF2T;DDX42;DDX54;DGCR8;DHX9;EIF4A3;ELAVL1;FAM120A;FBL;FUS;FXR1;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP2;KHDRBS1;KHDRBS3;KHSRP;LIN28;LIN28B;LSM11;MSI2;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM27;RBM47;RBM5;RNF219;SAFB2;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;ZNF184NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_HYPOXIA
ENSG00000245849.5,RAD51-AS1
ESCAEAGIRENSG00000100813.10chr1423064354:23066008:23067313:23068671-0.40831.6226e-038.3715e-08-0.4180imageNADAR;AUH;BCCIP;BUD13;CNBP;CPSF6;CSTF2T;DDX42;DDX54;DGCR8;DHX9;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FUS;FXR1;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP2;KHDRBS1;KHDRBS3;KHSRP;LARP7;LIN28;LIN28B;LSM11;MSI2;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM27;RBM47;RBM5;RNF219;SAFB2;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YWHAG;ZNF184ACIN1T_cells_CD4_memory_restingGSVA_HALLMARK_HYPOXIA
ENSG00000245849.5,RAD51-AS1
ESCAEAGESENSG00000150527.12chr1439319208:39319291:39320927:39321056:39326863:39327022-0.43552.7370e-049.1930e-12-0.5170imageNADAR;AUH;BCCIP;BUD13;CNBP;CPSF6;CSTF2T;DDX42;DDX54;DGCR8;DHX9;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FUS;FXR1;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP2;KHDRBS1;KHDRBS3;KHSRP;LARP7;LIN28;LIN28B;MSI2;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM47;RBM5;RNF219;SAFB2;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YWHAG;ZNF184NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_HYPOXIA
ENSG00000245849.5,RAD51-AS1
ESCAEAGIRENSG00000108439.5chr1747944615:47944715:47945860:47945912-0.30232.8017e-022.6036e-07-0.4530imageNADAR;AUH;BCCIP;BUD13;CNBP;CPSF6;CSTF2T;DDX42;DDX54;DGCR8;DHX9;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FUS;FXR1;GNL3;GTF2F1;HNRNPA1;HNRNPC;HNRNPK;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP2;KHDRBS1;KHSRP;LARP7;LIN28;LIN28B;LSM11;MSI2;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM27;RBM47;RNF219;SAFB2;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YWHAG;ZNF184NAB_cells_naiveGSVA_HALLMARK_P53_PATHWAY
ENSG00000245849.5,RAD51-AS1
ESCAEAGIRENSG00000016864.12chr352694488:52695302:52695420:52695554-0.43625.1390e-042.5047e-08-0.4331imageNADAR;AUH;BCCIP;BUD13;CPSF6;CSTF2T;DDX42;DDX54;DGCR8;DHX9;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FUS;FXR1;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP2;KHDRBS1;KHSRP;LARP7;LIN28;LIN28B;LSM11;MSI2;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM27;RBM47;RNF219;SAFB2;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YWHAG;ZNF184NAT_cells_CD4_memory_restingGSVA_HALLMARK_APICAL_JUNCTION
ENSG00000245849.5,RAD51-AS1
ESCAEAGESENSG00000144674.12chr337355100:37355187:37361242:37361305:37366079:37366745-0.37429.6371e-032.0461e-07-0.4064imageNADAR;AUH;BCCIP;BUD13;CNBP;CPSF6;CSTF2T;DDX42;DDX54;DGCR8;DHX9;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FUS;FXR1;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP2;KHDRBS1;KHDRBS3;KHSRP;LARP7;LIN28;LIN28B;LSM11;MSI2;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM47;RBM5;RNF219;SAFB2;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YWHAG;ZNF184NAB_cells_naiveGSVA_HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION
ENSG00000245849.5,RAD51-AS1
ESCAEAGIRENSG00000135469.9chr1256267681:56267940:56269058:56269108-0.31989.7101e-032.9539e-06-0.4288imageNAUH;BUD13;CNBP;CPSF6;CSTF2T;DDX42;DDX54;DGCR8;EIF4A3;ELAVL1;FAM120A;FBL;FUS;FXR1;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP2;KHDRBS1;KHSRP;LIN28;LIN28B;LSM11;NOP56;NUMA1;PCBP2;PRPF8;PTBP1;RBFOX2;SF3B4;SMNDC1;SND1;SRSF1;SRSF3;SRSF9;TAF15;TIA1;TROVE2;U2AF1;U2AF2;UPF1;XRN2;ZNF184NAMacrophages_M2GSVA_HALLMARK_GLYCOLYSIS
ENSG00000245849.5,RAD51-AS1
ESCAEAGIRENSG00000132640.10chr2011917777:11918011:11918333:11918463-0.35641.0303e-024.4243e-07-0.4128imageNAUH;BCCIP;BUD13;CNBP;CSTF2T;DDX54;DGCR8;DHX9;EIF4A3;ELAVL1;FAM120A;FBL;FUS;FXR1;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP2;KHDRBS1;KHDRBS3;KHSRP;LIN28;LIN28B;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM47;RBM5;RNF219;SAFB2;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TRA2A;U2AF1;U2AF2;UPF1;ZNF184NAT_cells_CD4_memory_restingGSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSE

More results



Top

5. Enriched editing regions and immune infiltration for RAD51-AS1


all structure

check button Associations of enriched editing regions with immune infiltration.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeIDImmuneCellPRCorrelationPlot
chr15:40688377-40688648:-BLCAEERB_cells_memory3.8834e-02-0.2391image
ENSG00000245849.5,RAD51-AS1BLCAEAGT_cells_regulatory_(Tregs)5.1846e-03-0.2817image
chr15:40690566-40694369:-BRCAEERDendritic_cells_activated8.7992e-030.1226image
ENSG00000245849.5,RAD51-AS1BRCAEAGMast_cells_resting1.6016e-02-0.1032image
chr15:40690566-40694369:-CESCEERNeutrophils1.7356e-030.5103image
chr15:40688377-40688648:-COADEERNK_cells_activated5.8933e-030.3879image
chr15:40690566-40694369:-COADEERMacrophages_M01.1454e-020.3118image
ENSG00000245849.5,RAD51-AS1COADEAGMast_cells_resting3.8548e-020.2304image
chr15:40690566-40694369:-ESCAEERT_cells_regulatory_(Tregs)1.3029e-03-0.2663image
ENSG00000245849.5,RAD51-AS1ESCAEAGMacrophages_M07.2212e-040.2713image
chr15:40688377-40688648:-GBMEERMast_cells_resting9.1636e-03-0.3393image
chr15:40690566-40694369:-GBMEEREosinophils3.4195e-02-0.3755image
ENSG00000245849.5,RAD51-AS1GBMEAGMast_cells_resting1.3509e-02-0.3097image
ENSG00000245849.5,RAD51-AS1HNSCEAGNeutrophils2.3322e-020.4612image
chr15:40688377-40688648:-KICHEERNeutrophils3.9529e-020.3354image
chr15:40690566-40694369:-KICHEERT_cells_CD4_memory_activated7.6400e-030.4208image
chr15:40688377-40688648:-KIRCEERMacrophages_M21.3767e-02-0.1956image
chr15:40690566-40694369:-KIRCEERT_cells_CD84.2270e-020.1569image
ENSG00000245849.5,RAD51-AS1KIRCEAGMacrophages_M21.3677e-02-0.1763image
chr15:40688377-40688648:-KIRPEERPlasma_cells1.3700e-020.2508image
chr15:40690566-40694369:-KIRPEERMacrophages_M04.3854e-020.2166image
ENSG00000245849.5,RAD51-AS1KIRPEAGMacrophages_M02.6279e-020.2037image
chr15:40688377-40688648:-LAMLEERMacrophages_M23.7710e-030.2583image
chr15:40690566-40694369:-LAMLEERDendritic_cells_activated4.4780e-020.1770image
ENSG00000245849.5,RAD51-AS1LAMLEAGT_cells_gamma_delta7.4538e-030.2229image
chr15:40688377-40688648:-LGGEERDendritic_cells_resting2.4917e-020.1551image
chr15:40690566-40694369:-LGGEERT_cells_follicular_helper2.2103e-02-0.1557image
ENSG00000245849.5,RAD51-AS1LGGEAGDendritic_cells_activated2.3381e-020.1357image
chr15:40688377-40688648:-LUADEERT_cells_follicular_helper2.0110e-020.1916image
chr15:40690566-40694369:-LUADEERNK_cells_activated4.4711e-03-0.2177image
chr15:40690566-40694369:-LUSCEERT_cells_CD4_naive4.1976e-030.2423image
ENSG00000245849.5,RAD51-AS1LUSCEAGT_cells_CD4_naive2.6741e-020.1582image
chr15:40690566-40694369:-OVEERDendritic_cells_resting6.4754e-030.1873image
ENSG00000245849.5,RAD51-AS1OVEAGT_cells_CD4_memory_resting3.1127e-02-0.1392image
chr15:40690566-40694369:-PAADEERB_cells_memory3.1217e-040.4722image
ENSG00000245849.5,RAD51-AS1PAADEAGB_cells_memory2.3597e-030.3681image
chr15:40690566-40694369:-PCPGEERDendritic_cells_resting4.8079e-030.4269image
ENSG00000245849.5,RAD51-AS1PCPGEAGMacrophages_M12.1141e-020.3022image
chr15:40688377-40688648:-PRADEERNK_cells_resting4.7161e-02-0.1242image
chr15:40690566-40694369:-PRADEERDendritic_cells_resting4.0851e-020.1118image
ENSG00000245849.5,RAD51-AS1PRADEAGMacrophages_M18.0390e-030.1374image
ENSG00000245849.5,RAD51-AS1READEAGMacrophages_M24.2328e-020.3268image
chr15:40690566-40694369:-SARCEERMacrophages_M11.7808e-020.3518image
ENSG00000245849.5,RAD51-AS1SARCEAGMonocytes3.0671e-020.2770image
chr15:40688377-40688648:-SKCMEERDendritic_cells_resting4.4818e-020.2324image
chr15:40690566-40694369:-SKCMEERT_cells_gamma_delta4.6505e-020.2016image
ENSG00000245849.5,RAD51-AS1SKCMEAGDendritic_cells_resting1.8231e-020.2161image
chr15:40690566-40694369:-STADEERNeutrophils3.1492e-02-0.1329image
ENSG00000245849.5,RAD51-AS1STADEAGB_cells_memory9.1790e-03-0.1494image
chr15:40688377-40688648:-TGCTEERMacrophages_M21.1391e-020.3961image
ENSG00000245849.5,RAD51-AS1TGCTEAGMast_cells_activated3.9985e-030.4164image
chr15:40690566-40694369:-THCAEERMast_cells_resting1.2677e-02-0.1276image
ENSG00000245849.5,RAD51-AS1THCAEAGMacrophages_M22.4090e-03-0.1489image
chr15:40688377-40688648:-THYMEERMacrophages_M04.7431e-030.3689image
ENSG00000245849.5,RAD51-AS1THYMEAGT_cells_CD84.2958e-02-0.2601image
chr15:40688377-40688648:-UCECEERMacrophages_M01.1399e-020.4975image
ENSG00000245849.5,RAD51-AS1UCECEAGMacrophages_M02.2057e-020.3754image


Top

6. Enriched editing regions and immune gene sets for RAD51-AS1


all structure

check button Correlation of enriched editing regions with epithelial-mesenchymal transition.
* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).
* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly edited between Epi and Mes group.
ID_eventscancerTypeE2M_PBoxplotCorPCorRCorrelationPlot


Top

check button Correlations of enriched editing regions with hypoxic.
* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.
* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.
ID_eventscancerTypeBuffa_P Buffa_R Ragnum_P Ragnum_R Winter_P Winter_R HALLMARK_P HALLMARK_R CorrelationPlot
ENSG00000245849.5,RAD51-AS1BRCAEAG3.4755e-050.17652.9514e-030.12724.8573e-030.12064.5993e-040.1497image
ENSG00000245849.5,RAD51-AS1KIRCEAG4.5110e-040.24893.3892e-020.15206.7800e-050.28137.7307e-050.2792image
ENSG00000245849.5,RAD51-AS1THCAEAG6.4479e-030.13384.5385e-020.09854.8265e-020.09724.9360e-070.2444image


Top

check button Associations of enriched editing regions with hallmark gene sets from MSigDB.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerHallmarkTypeTypePRCorrelationPlot
chr15:40688377-40688648:-BLCAGSVA_HALLMARK_GLYCOLYSISEER3.0584e-020.2499image
ENSG00000245849.5,RAD51-AS1BLCAGSVA_HALLMARK_HEDGEHOG_SIGNALINGEAG1.9340e-020.2372image
chr15:40690566-40694369:-BRCAGSVA_HALLMARK_APOPTOSISEER1.3067e-030.1501image
ENSG00000245849.5,RAD51-AS1BRCAGSVA_HALLMARK_GLYCOLYSISEAG4.9097e-070.2136image
ENSG00000245849.5,RAD51-AS1CESCGSVA_HALLMARK_ESTROGEN_RESPONSE_EARLYEAG4.5874e-020.2412image
chr15:40688377-40688648:-CESCGSVA_HALLMARK_NOTCH_SIGNALINGEER1.0003e-020.3415image
chr15:40690566-40694369:-CESCGSVA_HALLMARK_ESTROGEN_RESPONSE_EARLYEER3.3879e-020.3596image
ENSG00000245849.5,RAD51-AS1ESCAGSVA_HALLMARK_HYPOXIAEAG2.2691e-080.4343image
chr15:40690566-40694369:-ESCAGSVA_HALLMARK_HYPOXIAEER9.2203e-060.3614image
ENSG00000245849.5,RAD51-AS1GBMGSVA_HALLMARK_ESTROGEN_RESPONSE_LATEEAG6.7397e-030.3380image
chr15:40690566-40694369:-GBMGSVA_HALLMARK_PROTEIN_SECRETIONEER4.6026e-02-0.3552image
chr15:40688377-40688648:-GBMGSVA_HALLMARK_XENOBIOTIC_METABOLISMEER2.6788e-030.3872image
ENSG00000245849.5,RAD51-AS1HNSCGSVA_HALLMARK_MITOTIC_SPINDLEEAG1.9224e-020.4742image
chr15:40690566-40694369:-KICHGSVA_HALLMARK_ALLOGRAFT_REJECTIONEER4.6419e-020.3209image
chr15:40688377-40688648:-KICHGSVA_HALLMARK_PEROXISOMEEER3.8755e-020.3367image
ENSG00000245849.5,RAD51-AS1KICHGSVA_HALLMARK_PROTEIN_SECRETIONEAG4.2598e-02-0.2971image
chr15:40690566-40694369:-KIRCGSVA_HALLMARK_P53_PATHWAYEER1.9286e-070.3887image
ENSG00000245849.5,RAD51-AS1KIRCGSVA_HALLMARK_UV_RESPONSE_UPEAG3.8519e-080.3812image
chr15:40688377-40688648:-KIRCGSVA_HALLMARK_GLYCOLYSISEER3.9234e-050.3210image
chr15:40688377-40688648:-KIRPGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER3.1422e-020.2198image
ENSG00000245849.5,RAD51-AS1KIRPGSVA_HALLMARK_E2F_TARGETSEAG1.8852e-020.2150image
chr15:40688377-40688648:-LAMLGSVA_HALLMARK_BILE_ACID_METABOLISMEER1.6654e-02-0.2147image
ENSG00000245849.5,RAD51-AS1LGGGSVA_HALLMARK_FATTY_ACID_METABOLISMEAG7.4895e-040.2007image
chr15:40688377-40688648:-LGGGSVA_HALLMARK_FATTY_ACID_METABOLISMEER6.3176e-050.2731image
chr15:40688377-40688648:-LUADGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEER2.4988e-02-0.1849image
chr15:40690566-40694369:-LUADGSVA_HALLMARK_APICAL_JUNCTIONEER2.6945e-050.3169image
ENSG00000245849.5,RAD51-AS1LUADGSVA_HALLMARK_MITOTIC_SPINDLEEAG8.7487e-030.1797image
chr15:40688377-40688648:-LUSCGSVA_HALLMARK_PEROXISOMEEER6.3464e-030.2227image
chr15:40690566-40694369:-LUSCGSVA_HALLMARK_SPERMATOGENESISEER2.1069e-02-0.1962image
chr15:40690566-40694369:-OVGSVA_HALLMARK_COAGULATIONEER1.2318e-030.2215image
ENSG00000245849.5,RAD51-AS1OVGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEAG3.5022e-050.2637image
ENSG00000245849.5,RAD51-AS1PAADGSVA_HALLMARK_NOTCH_SIGNALINGEAG6.8513e-030.3298image
chr15:40690566-40694369:-PAADGSVA_HALLMARK_NOTCH_SIGNALINGEER6.0531e-040.4518image
chr15:40688377-40688648:-PCPGGSVA_HALLMARK_E2F_TARGETSEER3.6595e-02-0.3316image
ENSG00000245849.5,RAD51-AS1PCPGGSVA_HALLMARK_ALLOGRAFT_REJECTIONEAG4.2795e-020.2670image
chr15:40690566-40694369:-PCPGGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEER1.6304e-020.3686image
chr15:40690566-40694369:-PRADGSVA_HALLMARK_MITOTIC_SPINDLEEER1.2558e-080.3047image
ENSG00000245849.5,RAD51-AS1PRADGSVA_HALLMARK_MITOTIC_SPINDLEEAG2.3467e-070.2645image
ENSG00000245849.5,RAD51-AS1READGSVA_HALLMARK_MITOTIC_SPINDLEEAG3.2615e-020.3429image
ENSG00000245849.5,RAD51-AS1SARCGSVA_HALLMARK_MYOGENESISEAG5.5794e-030.3508image
chr15:40688377-40688648:-SARCGSVA_HALLMARK_HYPOXIAEER3.9775e-030.4123image
chr15:40690566-40694369:-SARCGSVA_HALLMARK_PI3K_AKT_MTOR_SIGNALINGEER1.2506e-030.4661image
ENSG00000245849.5,RAD51-AS1SKCMGSVA_HALLMARK_MYC_TARGETS_V2EAG9.7835e-030.2360image
chr15:40690566-40694369:-SKCMGSVA_HALLMARK_MYC_TARGETS_V1EER2.9964e-020.2194image
chr15:40688377-40688648:-SKCMGSVA_HALLMARK_PANCREAS_BETA_CELLSEER2.3146e-040.4130image
ENSG00000245849.5,RAD51-AS1STADGSVA_HALLMARK_UV_RESPONSE_UPEAG1.4650e-100.3574image
chr15:40690566-40694369:-STADGSVA_HALLMARK_NOTCH_SIGNALINGEER7.8802e-090.3471image
chr15:40690566-40694369:-TGCTGSVA_HALLMARK_KRAS_SIGNALING_UPEER4.1511e-02-0.3877image
chr15:40688377-40688648:-TGCTGSVA_HALLMARK_NOTCH_SIGNALINGEER2.1927e-040.5524image
ENSG00000245849.5,RAD51-AS1TGCTGSVA_HALLMARK_MYOGENESISEAG1.3402e-020.3621image
chr15:40690566-40694369:-THCAGSVA_HALLMARK_ANGIOGENESISEER8.1905e-050.2004image
ENSG00000245849.5,RAD51-AS1THCAGSVA_HALLMARK_ESTROGEN_RESPONSE_LATEEAG4.6440e-070.2450image
ENSG00000245849.5,RAD51-AS1THYMGSVA_HALLMARK_PANCREAS_BETA_CELLSEAG3.7136e-030.3661image
chr15:40690566-40694369:-THYMGSVA_HALLMARK_HEME_METABOLISMEER1.1827e-040.6124image
chr15:40688377-40688648:-UCECGSVA_HALLMARK_UV_RESPONSE_UPEER4.1168e-020.4112image
chr15:40690566-40694369:-UCECGSVA_HALLMARK_HEME_METABOLISMEER2.3530e-030.6143image
ENSG00000245849.5,RAD51-AS1UCECGSVA_HALLMARK_HEME_METABOLISMEAG7.6725e-030.4314image


Top

7. Enriched editing regions and drugs for RAD51-AS1


all structure

check button Correlations between enriched editing regions and drug sensitivity.
* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.
* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerDrugTypePRCorrelationPlot
chr15:40690566-40694369:-BLCAGSK269962AEER4.3582e-020.2492image
ENSG00000245849.5,RAD51-AS1BLCAAZD.2281EAG2.0109e-02-0.2357image
chr15:40688377-40688648:-BLCADocetaxelEER6.0396e-03-0.3142image
chr15:40690566-40694369:-BRCAATRAEER3.2434e-030.1379image
ENSG00000245849.5,RAD51-AS1BRCACyclopamineEAG1.0820e-03-0.1400image
chr15:40690566-40694369:-CESCBIBW2992EER1.2127e-02-0.4195image
ENSG00000245849.5,RAD51-AS1CESCFH535EAG1.4349e-02-0.2936image
chr15:40688377-40688648:-CESCBIRB.0796EER3.6349e-02-0.2804image
chr15:40690566-40694369:-COADBosutinibEER1.1537e-020.3115image
chr15:40688377-40688648:-COADMidostaurinEER4.1132e-02-0.2929image
ENSG00000245849.5,RAD51-AS1COADBosutinibEAG8.5639e-040.3633image
ENSG00000245849.5,RAD51-AS1ESCAJNJ.26854165EAG4.5244e-05-0.3256image
chr15:40690566-40694369:-ESCAErlotinibEER3.0234e-04-0.2979image
chr15:40690566-40694369:-GBMGW843682XEER1.7927e-03-0.5304image
ENSG00000245849.5,RAD51-AS1GBMCGP.082996EAG2.7612e-03-0.3710image
chr15:40688377-40688648:-GBMGNF.2EER3.9173e-03-0.3731image
ENSG00000245849.5,RAD51-AS1HNSCBX.795EAG2.4622e-02-0.4574image
chr15:40690566-40694369:-KICHAKT.inhibitor.VIIIEER4.4223e-020.3240image
ENSG00000245849.5,RAD51-AS1KICHBAY.61.3606EAG2.2505e-030.4349image
chr15:40688377-40688648:-KICHKIN001.135EER2.3681e-03-0.4786image
ENSG00000245849.5,RAD51-AS1KIRCCCT007093EAG1.7188e-060.3348image
chr15:40690566-40694369:-KIRCBortezomibEER5.2654e-05-0.3067image
chr15:40688377-40688648:-KIRCCMKEER7.4971e-05-0.3097image
ENSG00000245849.5,RAD51-AS1KIRPEHT.1864EAG1.2259e-020.2290image
chr15:40690566-40694369:-KIRPGSK.650394EER7.5426e-030.2846image
chr15:40688377-40688648:-KIRPCEP.701EER1.3708e-02-0.2508image
chr15:40690566-40694369:-LAMLJNJ.26854165EER3.9159e-02-0.1818image
ENSG00000245849.5,RAD51-AS1LAMLGDC0941EAG3.7054e-02-0.1746image
chr15:40688377-40688648:-LAMLGW.441756EER7.7850e-030.2380image
ENSG00000245849.5,RAD51-AS1LGGIPA.3EAG3.7465e-030.1730image
chr15:40688377-40688648:-LGGEmbelinEER4.2150e-040.2417image
chr15:40690566-40694369:-LGGDocetaxelEER2.2563e-020.1551image
ENSG00000245849.5,RAD51-AS1LUADAZ628EAG3.1935e-02-0.1495image
chr15:40690566-40694369:-LUADFH535EER5.3320e-03-0.2134image
chr15:40688377-40688648:-LUADCCT018159EER2.4209e-020.1858image
ENSG00000245849.5,RAD51-AS1LUSCJNK.9LEAG4.6808e-02-0.1422image
chr15:40690566-40694369:-LUSCJNK.9LEER2.9480e-02-0.1854image
chr15:40688377-40688648:-LUSCCCT007093EER9.6543e-040.2677image
chr15:40690566-40694369:-OVEtoposideEER5.9886e-040.2349image
ENSG00000245849.5,RAD51-AS1OVBMS.536924EAG1.7293e-05-0.2735image
chr15:40690566-40694369:-PAADBexaroteneEER2.4436e-02-0.3060image
ENSG00000245849.5,RAD51-AS1PAADAxitinibEAG4.6483e-020.2460image
chr15:40690566-40694369:-PCPGDocetaxelEER7.1295e-03-0.4092image
ENSG00000245849.5,RAD51-AS1PCPGDocetaxelEAG2.4301e-02-0.2955image
chr15:40688377-40688648:-PRADJNK.Inhibitor.VIIIEER3.3549e-020.1329image
chr15:40690566-40694369:-PRADBryostatin.1EER5.5979e-070.2694image
ENSG00000245849.5,RAD51-AS1PRADBryostatin.1EAG3.4021e-080.2817image
ENSG00000245849.5,RAD51-AS1READElesclomolEAG1.6632e-020.3813image
chr15:40688377-40688648:-SARCGNF.2EER1.0069e-03-0.4644image
chr15:40690566-40694369:-SARCBIRB.0796EER3.7981e-030.4229image
ENSG00000245849.5,RAD51-AS1SARCBIRB.0796EAG3.7428e-050.5021image
chr15:40690566-40694369:-SKCMGW843682XEER1.9057e-02-0.2365image
chr15:40688377-40688648:-SKCMBIBW2992EER3.0947e-030.3372image
ENSG00000245849.5,RAD51-AS1SKCMEpothilone.BEAG2.1267e-02-0.2110image
chr15:40690566-40694369:-STADAxitinibEER4.2907e-04-0.2160image
ENSG00000245849.5,RAD51-AS1STADGefitinibEAG1.0090e-020.1481image
chr15:40690566-40694369:-TGCTCMKEER1.0089e-02-0.4780image
chr15:40688377-40688648:-TGCTAUY922EER3.9857e-04-0.5330image
ENSG00000245849.5,RAD51-AS1TGCTAS601245EAG2.5450e-03-0.4346image
chr15:40690566-40694369:-THCACEP.701EER6.3750e-030.1397image
ENSG00000245849.5,RAD51-AS1THCACI.1040EAG1.2747e-03-0.1580image
ENSG00000245849.5,RAD51-AS1THYMCMKEAG1.6738e-040.4637image
chr15:40688377-40688648:-THYMAP.24534EER2.7192e-020.2926image
chr15:40690566-40694369:-THYMBMS.536924EER6.2599e-050.6312image
ENSG00000245849.5,RAD51-AS1UCECBryostatin.1EAG6.8726e-030.4368image
chr15:40688377-40688648:-UCECGNF.2EER5.6011e-03-0.5374image
chr15:40690566-40694369:-UCECAZD6244EER3.1936e-040.7091image


Top

check button EAGs targeted by drugs from DrugBank database.
* EAG: EER-associated genes.
EERENSTUniprotIDDrugBankIDDrugDrugType